368 related articles for article (PubMed ID: 26463526)
1. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
[TBL] [Abstract][Full Text] [Related]
2. Initiation of antiretroviral therapy after the critical neuronal developmental period of the second postnatal year affects white matter microstructure in adolescents living with HIV.
Hoare J; Heany SJ; Fouche JP; Phillips N; Joska JA; Myer L; Zar HJ; Stein DJ
J Neurovirol; 2019 Apr; 25(2):254-262. PubMed ID: 30617850
[TBL] [Abstract][Full Text] [Related]
3. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
4. Subtype associations with HIV-associated neurocognitive disorder in China.
Day TR; Smith DM; Heaton RK; Franklin D; Tilghman MW; Letendre S; Jin H; Wu Z; Shi C; Yu X; Pérez-Santiago J
J Neurovirol; 2016 Apr; 22(2):246-50. PubMed ID: 26306690
[TBL] [Abstract][Full Text] [Related]
5. Trajectories of Depressive Symptoms, Neurocognitive Function, and Viral Suppression With Antiretroviral Therapy Among Youth With HIV Over 36 months.
Kohn JN; Loop MS; Kim-Chang JJ; Garvie PA; Sleasman JW; Fischer B; Rendina HJ; Woods SP; Nichols SL; Hong S
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):851-859. PubMed ID: 33587499
[TBL] [Abstract][Full Text] [Related]
6. The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.
Harrison JD; Dochney JA; Blazekovic S; Leone F; Metzger D; Frank I; Gross R; Hole A; Mounzer K; Siegel S; Schnoll RA; Ashare RL
J Neurovirol; 2017 Aug; 23(4):550-557. PubMed ID: 28429289
[TBL] [Abstract][Full Text] [Related]
7. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
9. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
Gezie LD
BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
[TBL] [Abstract][Full Text] [Related]
10. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV.
Kim-Chang JJ; Donovan K; Loop MS; Hong S; Fischer B; Venturi G; Garvie PA; Kohn J; Rendina HJ; Woods SP; Goodenow MM; Nichols SL; Sleasman JW;
AIDS; 2019 Dec; 33(15):2363-2374. PubMed ID: 31764101
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.
Nichols SL; Bethel J; Garvie PA; Patton DE; Thornton S; Kapogiannis BG; Ren W; Major-Wilson H; Puga A; Woods SP
J Adolesc Health; 2013 Dec; 53(6):763-71. PubMed ID: 23972941
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
13. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
[TBL] [Abstract][Full Text] [Related]
14. Relation of Steatosis to Neurocognitive Function in People Living with HIV.
Marić D; Brkić S; Ignjatović VB; Nikolaševic Ž; Ilić D; Vujanović M; Drvendžija Z; Galić BS
Curr HIV Res; 2020; 18(3):172-180. PubMed ID: 32106801
[TBL] [Abstract][Full Text] [Related]
15. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
[TBL] [Abstract][Full Text] [Related]
16. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
[TBL] [Abstract][Full Text] [Related]
17. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
18. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
Sacktor N
J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
[TBL] [Abstract][Full Text] [Related]
19. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
